butabarbital decreases effects of sufentanil SL by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Intently. Coadministration of CYP3A4 inducers may perhaps minimize sufentanil concentrations and efficacy, potentially precipitating withdrawal syndrome in patients that have developed Actual physical dependence to sufentan